Adaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 2026
Rhea-AI Summary
Adaptive Biotechnologies (Nasdaq: ADPT) will report first quarter 2026 financial results after market close on May 5, 2026. Management will host a live webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET, with archived replay available within 24 hours.
Investors can access live audio via the company’s Investors website.
Positive
- None.
Negative
- None.
News Market Reaction – ADPT
In the Apr 16 session, ADPT declined 3.10%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 22 | Earnings date notice | Neutral | -2.7% | Set timing for Q4 and FY2025 results and investor webcast. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Prior earnings date scheduling news was followed by a -2.68% move, suggesting past sensitivity around these announcements.
Recent news shows ADPT progressing through a series of investor-related events. An earlier earnings date notice on Jan 22, 2026 outlined timing for Q4 and full-year 2025 results and a webcast at 1:30 p.m. PT / 4:30 p.m. ET, which preceded a -2.68% move. Today’s announcement similarly schedules the Q1 2026 report and webcast details, fitting into a consistent pattern of formal communication around earnings.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SEATTLE, April 15, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the first quarter 2026 after market close on Tuesday, May 5, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Live audio of the webcast will be available on the “Investors” section of the company website at: www.adaptivebiotech.com. The webcast will be archived and available for replay within 24 hours after the event.
About Adaptive Biotechnologies
Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business segments: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer and autoimmune disorders. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.
ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations and FP&A
201-396-1687
investors@adaptivebiotech.com
ADAPTIVE MEDIA
Erica Jones, Associate Corporate Communications Director
206-279-2423
media@adaptivebiotech.com
